CureDuchenne Branded - Dual-Liner Face Mask (Adult)4 × $8.00
Exon Branded - Dual-Liner Face Mask (Youth)4 × $8.00
CureDuchenne and Catabasis Pharmaceuticals, Inc. hosted a webinar “MoveDMD: A Clinical Trial of Edasalonexent (CAT-1004) in Boys with Duchenne Muscular Dystrophy” on Wednesday, June 22, 2016.
Dr. Donovan discussed the positive results from Part A of the MoveDMD trial and reviewed the design and inclusion criteria of Part B (Phase 2) that is currently running. The MoveDMD trial is a Phase 1/2 clinical trial of edasalonexent in boys with Duchenne between the ages of 4 and 7. The goal of Part A included evaluation of the safety and tolerability of edasalonexent. Part B will evaluate the safety and efficacy of edasalonexent in boys with Duchenne.
Dr. Donovan, who received her academic training at MIT, Harvard and Brigham & Women’s Hospital, has more than 15 years of experience in drug development, taking programs from Phase 1 to approval. Dr. Donovan is currently an Associate Clinical Professor of Medicine at Harvard and continues to practice and teach medicine.
Click here to watch the recording of the webinar. You’ll be prompted to enter your name and email address to view the recording.